Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the decision memo for allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome emanating from the Centers for Medicare and Medicaid Services

Journal of Clinical Oncology

Volumn 29, Issue 5, 2011, Pages 566-572

  Giralt, Sergio A ^a   Horowitz, Mary ^a   Weisdorf, Daniel ^a   Cutler, Corey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER STAGING; ELDERLY CARE; HEALTH SERVICE; HUMAN; MEDICAID; MEDICARE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MEDICAID; MEDICARE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 79952076075     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.1919     Document Type: Review

References (70)

1. Dansey R: Myelodysplasia. Curr Opin Oncol 12:13-21, 2000
2. Aul C, Germing U, Gattermann N, et al: Increasing incidence of myelodysplastic syndromes: Real or fictitious? Leuk Res 22:93-100, 1998
3. Ma X, Does M, Raza A, et al: Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 109:1536-1542, 2007 (Pubitemid 46595689)
4. Goldberg S, Chen E, Corral M, et al: Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 28:2847-2852, 2010
5. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002 (Pubitemid 34525728)
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized, open-label, phase III study. Lancet 10:223-232, 2009
7. Kantarjian H, Issa J-P, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 106:1794-1803, 2006
8. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006 (Pubitemid 44511560)
9. Faderl S, Garcia-Manero G, Estrov Z, et al: Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 28:2755-2760, 2010
10. Appelbaum FR, Storb R, Ramberg RE, et al: Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med 100:689-693, 1984 (Pubitemid 14143944)
11. Appelbaum FR, Storb R, Ramberg RE, et al: Treatment of preleukemia syndromes with marrow transplantation. Blood 69:92-96, 1987 (Pubitemid 17007080)
12. Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndromes: Outcomes analysis according to IPSS scores. Leukemia 12:S25-S29, 1998 (suppl 1) (Pubitemid 28479000)
13. de Witte T, Hermans J, Vossen J, et al: Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemia: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620-630, 2000
14. Sierra J, Pérez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002
15. Sutton L, Chastang C, Ribaud P, et al: Factors influencing outcome in de-novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88: 358-365, 1996 (Pubitemid 26230708)
16. Anderson J, Anasetti C, Appelbaum F, et al: Unrelated donor bone marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Br J Haematol 93:59-67, 1996 (Pubitemid 26130716)
17. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor transplantation for myelodysplastic syndromes: Outcomes of analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002
18. de Witte T, Pikkemaat F, Hermans J, et al: Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: Comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 15:1878-1884, 2001
19. Oostervald M, Suciu S, Verhoef G, et al: The presence of an HLA-identical sibling donor has no impact on outcomes of patients with high risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK, and GIMEMA Leukemia groups (EORTC 06921). Leukemia 17:859-868, 2003
20. Deeg HJ, Shulman HM Anderson JE, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 65 years of age. Blood 95:1188-1194, 2000 (Pubitemid 30099825)
21. National Comprehensive Cancer Network: The NCCN 2.2010 Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology. Fort Washington, PA, National Comprehensive Cancer Network, 2010
22. Oliansky DM, Antin JH, Bennett JM, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: An evidence-based review. Biol Blood Marrow Transplant 15:137-172, 2009
23. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997 (Pubitemid 27260263)
24. Slavin S, Nagler A, Naperstek E, et al: Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 91:756-763, 1998 (Pubitemid 28078275)
25. Giralt S, Anagnostopoulos A, Shahjahan M, et al: Non-ablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 39:57-62, 2002 (Pubitemid 34081157)
26. Pasquini MC, Wang Z: Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010. http://www.cibmtr.org/ ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx
27. Jacques LB, Syrek T, Salive ME, et al: Decision memorandum for allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome August 4, 2010. Center for Medicare and Medicaid Services. http://www.cms.gov/mcd/ viewdecisionmemo.asp?from2=viewdecisionmemo. asp&id=238&
28. Nimer S: Myelodysplastic syndromes. Blood 111:4841-4851, 2008
29. Greenberg P: Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 150:131-143, 2010
30. McClune B, Weisdorf D, Pedersen T, et al: Effect of age on outcome of reduced intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndromes. J Clin Oncol 28:1878-1887, 2010
31. Greenberg P, Cox C, LeBeau M, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
32. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982 (Pubitemid 12073508)
33. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues; report of the Clinical Advisory Committee Meeting, Arlie House, Virginia, November 1997. Histopathology 36:68-87, 2000
34. Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005 (Pubitemid 46291823)
35. Malcovati L, Della Porta MG, Cazzola M: Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91: 1588-1590, 2006 (Pubitemid 46032954)
36. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007 (Pubitemid 47315575)
37. Kantarjian H, O'Brien S, Ravandi F, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361, 2008
38. Garcia-Manero G, Shan J, Faderl S, et al: A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22:538-543, 2008 (Pubitemid 351386723)
39. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002 (Pubitemid 34864272)
40. De Witte T, Brand R, Van Biezen A, et al: Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: Delay of the transplant is associated with inferior survival. Br J Haematol 146:627-636, 2009
41. Platzbecker U, Bornhauser M, Germing U, et al: Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 14:1217-1225, 2008
42. Alessandrino EP, Della Porta MG, Bacigalupo A, et al: WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895-902, 2008
43. Dayyani F, Conley AP, Strom SS, et al: Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116:2174-2179, 2010
44. Armand P, Kim HT, Cutler CS, et al: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586-4588, 2007 (Pubitemid 46743431)
45. Pullarkat V, Blanchard S, Tegtmeier B, et al: Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 42:799-805, 2008
46. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007 (Pubitemid 351377805)
47. Mills KI, Kohlmann A, Williams PM, et al: Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063-1072, 2009
48. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004 (Pubitemid 38900045)
49. De Padua SL, de Lima M, Kantarjian H, et al: Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839-843, 2009
50. Field T, Perkins J, Huang Y, et al: 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 45: 255-260, 2010
51. Alyea EP, Kim HT, Ho V, et al: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047-1055, 2006 (Pubitemid 44603937)
52. Martino R, Iacobelli S, Brand R, et al: Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846, 2006 (Pubitemid 44154615)
53. Andersson BS, Gajewski J, Donato M, et al: Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 25:S35-S38, 2000
54. Litzow MR, Tarima S, Perez WS, et al: Allogeneic transplantation for therapy related myelodysplastic syndrome and acute myeloid leukemia. Blood 115:1850-1857, 2010
55. Oostervald M, Muus P, Suciu S, et al: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16:1615-1621, 2003
56. Nakai K, Kanda Y, Fukuhara S, et al: Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19:396-401, 2005 (Pubitemid 40403316)
57. Scott BL, Storer B, Loken MR, et al: Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65-73, 2005 (Pubitemid 40057995)
58. Lim ZY, Brand R, Martino R, et al: Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28:405-411, 2009
59. Laport GG, Sandmaier BM, Storer BE, et al: Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 14:246-255, 2008
60. Giralt S, Champlin R: Leukemia relapse after allogeneic bone marrow transplantation. A review. Blood 84:3603-3612, 1994 (Pubitemid 24362455)
61. Ferrara J, Deeg H: Graft versus host disease. N Engl J Med 324:667-674, 1991
62. de Lima M, Anagnostopoulos A, Munsell M, et al: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865-872, 2004 (Pubitemid 38970586)
63. Luger S, Ringden O, Perez WS, et al: Similar outcomes using myeloablative versus reduced intensity and non-myeloablative allogeneic transplant preparative regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research. Blood 112:348, 2008
64. Andersson BS, Kashyap A, Gian V, et al: Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 8:145-154, 2002 (Pubitemid 34285073)
65. Slattery JT, Risler LJ: Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20:543-, 1998
66. Russell JA, Tran HT, Quinlan D, et al: Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 468-476, 2002 (Pubitemid 35174820)
67. De Lima M, Couriel D, Thall PF, et al: Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104:857-864, 2004 (Pubitemid 38970585)
68. Alatrash G, Andersson BS, Pelosini M, et al: Myeloablative, reduced toxicity IV busulfan/fludarabine (BuFlu) and allogeneic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS. Blood 112:2999, 2008
69. Sorror ML, Sandmaier BM, Storer BE, et al: Co-morbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25:4246-4254, 2007 (Pubitemid 47554249)
70. Artz AS, Pollyea D, Kocherginsky M, et al: Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation. Biol Blood and Marrow Transplant 12:954-964, 2006